Table 1.
Patient characteristics
| Dabigatran (n=45) | Nadroparine (n=45) | Rivaroxaban (n=48) | Total (n=138) | |
| Female, n (%) | 26 (58) | 31 (69) | 30 (63) | 87 (63) |
| Age (year) (±SD) | 66±7.9 | 67±10 | 65±7.5 | 66±8.7 |
| Weight (kg) (±SD) | 88±12 | 89±18 | 90±21 | 89±17 |
| Fast-track surgery, n (%) | 41 (91) | 35 (78) | 35 (73) | 111 (80) |
| Received new patella, n (%) | 7 (16) | 10 (22) | 16 (33) | 33 (24) |
| History of VTE, n (%) | 1 (2.2) | 1 (2.2) | 2 (4.2) | 4 (2.9) |
| Time to first dose (hours) (±SD) | 8.6±2.3 | 9±2.2 | 8.8±2.1 | 8.8±2.2 |
| Presurgery KOOS (±SD) | ||||
| Pain (n) | 47±15 (32) | 48±20 (35) | 51±21 (35) | 49±19 (102) |
| Symptoms (n) | 55±16 (32) | 49±18 (35) | 50±18 (35) | 51±17 (102) |
| ADL (n) | 52±15 (32) | 48±19 (35) | 56±19 (35) | 52±18 (102) |
| Sport and recreation (n) | 23±25 (29) | 24±28 (31) | 22±22 (29) | 23±25 (89) |
| Quality of life (n) | 30±12 (31) | 30±16 (35) | 30±15 (35) | 30±14 (101) |
ADL, activities of daily living function; KOOS, Knee Injury and Osteoarthritis Outcome Score; VTE, venous thromboembolism.